Johnson & Johnson's amivantamab (Rybrevant Faspro) won accelerated FDA approval for pretreated recurrent head and neck cancer.
|Articles|May 15, 2017
- BioPharm International-05-15-2017
- Volume 2017 eBook
- Issue 1
Operations and Quality Oversight of CMOs
Author(s)Hope Mueller
Effective communication between contract manufacturing organizations and pharmaceutical company clients relies on well-defined master service and quality agreements.
Advertisement
CMO partnerships can be challenging both for the CMO and the product owner. The article maps out optimal organizational designs for CMOs and product owners that increase the likelihood of a successful partnership and ensure consistent, reliable, and quality supply of drug product.
Articles in this issue
over 9 years ago
Customer Relationship Management in Contract Manufacturingover 9 years ago
Getting Biopharmaceutical Tech Transfer Right the First Timeover 9 years ago
CMOs Tackle New Challengesover 9 years ago
Gearing Up for Biosimilarsover 9 years ago
Insourcing vs Outsourcing: Choosing the Right Strategyover 9 years ago
Quality Metrics and CMO AgreementAdvertisement
Related to this article
FDA’s draft framework would let sponsors add patient-specific genome editing variants to an approved BLA using in vitro data. Here is what the guidance proposes, what evidence it asks for, and what remains unresolved.
Akeso won NMPA priority review for ivonescimab plus chemotherapy in first-line biliary tract cancer after a phase 3 win over durvalumab plus chemo.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Final FDA guidance replaces 2011 potency testing advice, asking CGT makers to build potency assurance from IND filing through postmarket monitoring.
CAR-T transformed blood cancer care, but solid and brain tumors demand different delivery, manufacturing, and safety strategies to work.
Samsung Biologics' pending PolyPeptide deal adds peptide API manufacturing, including GLP-1 supply, to its antibody and ADC CDMO services.
Inovio reports that Voceryq spared 27% of adults with recurrent respiratory papillomatosis from surgery for 12 months in a 26-patient efficacy group.
Advertisement
Advertisement
Trending on BioPharm International
1
Caldera’s IL-23p19×TL1A Bispecific CLD-423 Shows 40-Day Half-Life in Phase 1a, Supporting Dosing Every 8 to 12 Weeks
2
China Grants Ivonescimab Priority Review in Biliary Tract Cancer
3
VeonGen Aligns with FDA on Phase 3 Design for Stargardt Gene Therapy
4
FAQ: What FDA’s Individualized Gene Editing Draft Guidance Means for Developers
5